The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Status
- RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
- Status
- UNKNOWN
- Phase
- NA
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Status
- RECRUITING
- Phase
- PHASE1
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Natural Killer(NK) Cell Therapy in r/r AML
- Status
- RECRUITING
- Phase
- PHASE1
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
- Status
- TERMINATED
- Phase
- PHASE1